Quinapril

The dosage of Quinapril is highly individualized based on the patient's clinical response and the condition being treated.

Hypertension

For adults not on a diuretic, the recommended initial starting dose is 10 mg or 20 mg once daily. Depending on the blood pressure response, the dosage may be adjusted at intervals of at least two weeks. Most patients are maintained on a dose of 20 mg, 40 mg, or 80 mg per day, administered as a single dose or divided into two equal doses. If blood pressure is not controlled with Quinapril alone, a diuretic may be added. For patients already taking a diuretic, the healthcare provider may discontinue the diuretic 2 to 3 days before starting Quinapril or start with a lower initial dose of 5 mg to prevent an excessive drop in blood pressure (hypotension).

Heart Failure

The recommended starting dose for patients with heart failure is 5 mg twice daily. This dose should be titrated upward weekly based on the patient's tolerance and clinical response. The usual effective maintenance dose ranges from 20 mg to 40 mg daily, administered in two equally divided doses. Healthcare providers will closely monitor the patient's blood pressure and renal function during the titration phase.

Quinapril is generally not recommended for use in pediatric patients. While some ACE inhibitors have been studied in children, the safety and effectiveness of Quinapril in patients under the age of 18 have not been established. If a child requires blood pressure medication, a pediatric cardiologist or nephrologist will select an alternative agent with established safety data for that age group.

Renal Impairment

Since Quinapril is primarily eliminated by the kidneys, dosage adjustments are critical for patients with reduced kidney function. For patients with a creatinine clearance (CrCl) between 30 and 60 mL/min, the starting dose is 5 mg once daily. For those with a CrCl between 10 and 30 mL/min, the starting dose is reduced to 2.5 mg once daily. If the CrCl is less than 10 mL/min, there is insufficient data to recommend a specific dose, and extreme caution is required.

Hepatic Impairment

In patients with liver cirrhosis or impaired hepatic function, the conversion of Quinapril to its active metabolite, quinaprilat, may be delayed or reduced. While specific dose adjustment protocols are not always standardized for liver disease, healthcare providers will monitor these patients closely for efficacy and potential side effects.

Elderly Patients

Older adults (65 years and older) may be more sensitive to the effects of Quinapril. Clinical studies suggest that while efficacy is similar to younger patients, the risk of dizziness or renal impairment may be higher. Starting at the lower end of the dosing range (e.g., 10 mg) is often prudent for geriatric patients.

Quinapril should be taken exactly as prescribed by your doctor. It is typically taken once or twice daily. It can be taken with or without food; however, high-fat meals may slightly decrease the rate of absorption. For consistency, it is best to take it at the same time(s) each day. If you are taking the tablet form, swallow it whole with a glass of water. Do not crush or chew the tablets unless specifically instructed by your pharmacist. Store the medication at room temperature, away from moisture, heat, and direct light. Keep the bottle tightly closed when not in use.

If you miss a dose of Quinapril, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of severe hypotension (low blood pressure).

Symptoms of a Quinapril overdose may include severe hypotension (feeling faint or passing out), electrolyte imbalances, and kidney failure. If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on restoring blood pressure through intravenous fluids and monitoring vital signs.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without explicit medical guidance, as sudden discontinuation can cause your blood pressure to rise rapidly.

Like all medications, Quinapril can cause side effects, although not everyone experiences them. The most frequently reported side effect associated with Quinapril and other ACE inhibitors is a persistent, dry, non-productive cough. This occurs because the drug prevents the breakdown of bradykinin in the lungs. This cough typically does not respond to cough suppressants and usually only resolves once the medication is discontinued. Other common side effects include:

• Dizziness or Lightheadedness: Especially when rising from a sitting or lying position (orthostatic hypotension), occurring most frequently after the first dose or after a dose increase.
• Fatigue: A general feeling of tiredness or lack of energy as the body adjusts to lower blood pressure levels.
• Headache: Mild to moderate headaches are common during the initial weeks of therapy.

Some patients may experience the following side effects, which should be monitored and reported to a healthcare provider if they persist:

• Nausea and Vomiting: Gastrointestinal upset is possible but usually mild.
• Diarrhea or Abdominal Pain: Changes in bowel habits or stomach discomfort.
• Hyperkalemia: An increase in blood potassium levels. Symptoms may include muscle weakness or an irregular heartbeat. This is more common in patients with kidney disease or those taking potassium supplements.
• Myalgia: Muscle aches or pains.
• Rhinitis: Inflammation of the nasal mucosa, leading to a runny or stuffy nose.

Rare but documented side effects include:

• Photosensitivity: Increased sensitivity of the skin to sunlight, leading to easier sunburn.
• Taste Disturbance (Dysgeusia): A metallic or salty taste in the mouth.
• Sleep Disturbances: Insomnia or unusual dreams.
• Paresthesia: A sensation of tingling or "pins and needles" in the extremities.

> Warning: Stop taking Quinapril and call your doctor immediately or seek emergency care if you experience any of the following:

• Angioedema: This is a life-threatening allergic reaction characterized by swelling of the face, lips, tongue, or throat. It can cause severe difficulty breathing or swallowing. This reaction can occur at any time during treatment, even after months of safe use.
• Liver Toxicity: Symptoms include yellowing of the skin or eyes (jaundice), dark urine, severe right-sided abdominal pain, and intense itching. ACE inhibitors have rarely been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis.
• Neutropenia/Agranulocytosis: A severe decrease in white blood cells, which can make you more susceptible to infections. Symptoms include fever, sore throat, and chills.
• Kidney Failure: Signs include changes in the amount or frequency of urination, swelling in the ankles or feet, and shortness of breath.
• Severe Hypotension: Fainting or extreme dizziness that does not go away.

Prolonged use of Quinapril is generally well-tolerated; however, long-term monitoring of renal function and potassium levels is essential. In some patients, chronic ACE inhibition can lead to a gradual decline in kidney function, particularly in those with pre-existing renal artery stenosis (narrowing of the arteries to the kidneys). There is no evidence that Quinapril causes cumulative toxicity or addiction over time.

Fetal Toxicity: Quinapril carries a Boxed Warning regarding its use during pregnancy. When pregnancy is detected, Quinapril should be discontinued as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus, especially during the second and third trimesters. Risks include skull hypoplasia (underdevelopment), anuria (lack of urine production), reversible or irreversible renal failure, and death of the fetus. If you are planning to become pregnant or find out you are pregnant, contact your doctor immediately to switch to a safer antihypertensive alternative.

Report any unusual symptoms to your healthcare provider immediately. Your doctor may perform regular blood tests to check your kidney function and potassium levels while you are taking this medication.

Quinapril is a potent medication that requires careful medical supervision. It is not suitable for everyone, and certain precautions must be observed to ensure safety. Patients must be aware that the first few doses of Quinapril may cause a significant drop in blood pressure, especially if they are also taking diuretics or are dehydrated. It is recommended to take the first dose at bedtime or under conditions where you can sit or lie down if dizziness occurs. Furthermore, because Quinapril can affect kidney function and electrolyte balance, regular laboratory monitoring is a standard part of therapy.

Fetal Toxicity Warning: Quinapril can cause serious injury or death to an unborn baby if taken during pregnancy. Use of drugs that act on the renin-angiotensin system during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios (low amniotic fluid) can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Quinapril as soon as possible.

• Angioedema Risk: There is a risk of angioedema (swelling of deep skin layers), particularly involving the head and neck. This risk is statistically higher in Black patients compared to non-Black patients. If swelling of the face, extremities, eyes, lips, or tongue occurs, or if there is difficulty swallowing or breathing, the drug must be stopped immediately.
• Hypotension (Low Blood Pressure): Excessive hypotension is rare in uncomplicated hypertensive patients but may occur in those who are salt/volume depleted due to prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Heart failure patients are also at higher risk.
• Impaired Renal Function: In patients with severe heart failure or underlying renal artery stenosis, Quinapril may cause a rapid decline in kidney function. Healthcare providers will monitor serum creatinine levels closely.
• Hyperkalemia: Because Quinapril reduces aldosterone levels, it can lead to the retention of potassium. Patients should avoid using potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium without consulting their doctor.
• Surgery/Anesthesia: If you are scheduled for surgery, inform your surgeon or anesthesiologist that you are taking Quinapril. It may interact with anesthetic agents, leading to a profound drop in blood pressure.

To ensure the safe use of Quinapril, your healthcare provider will likely order the following tests periodically:

• Serum Creatinine and BUN: To monitor kidney function.
• Serum Potassium: To ensure levels do not become dangerously high.
• Complete Blood Count (CBC): Occasionally checked to monitor for rare blood disorders like neutropenia.
• Blood Pressure: Regular home and office monitoring to ensure the medication is working effectively.

Quinapril can cause dizziness, lightheadedness, or fatigue, especially during the first few days of treatment or when the dose is increased. Do not drive, operate heavy machinery, or engage in hazardous activities until you know how this medication affects you. If you feel dizzy, sit or lie down immediately.

Alcohol can enhance the blood-pressure-lowering effect of Quinapril, which may lead to severe dizziness, fainting, or a rapid heartbeat. It is generally advised to limit or avoid alcohol consumption while taking this medication, particularly during the initiation phase of therapy.

Do not stop taking Quinapril suddenly unless you experience a serious allergic reaction. Abruptly stopping blood pressure medication can cause "rebound hypertension," where your blood pressure spikes to dangerously high levels. If the medication needs to be stopped, your doctor will usually provide a plan to taper the dose gradually.

> Important: Discuss all your medical conditions, including history of kidney disease, liver disease, or heart problems, with your healthcare provider before starting Quinapril.

There are certain medications that should never be used in combination with Quinapril due to the risk of severe adverse reactions:

• Aliskiren: In patients with diabetes or renal impairment (GFR < 60 mL/min), the combination of Quinapril and aliskiren (a direct renin inhibitor) is strictly contraindicated. This combination significantly increases the risk of kidney failure, hyperkalemia, and severe hypotension.
• Sacubitril/Valsartan (Entresto): Quinapril must not be taken within 36 hours of taking sacubitril/valsartan. Combining an ACE inhibitor with a neprilysin inhibitor greatly increases the risk of life-threatening angioedema.

• Lithium: Quinapril can reduce the renal clearance of lithium, leading to toxic levels of lithium in the blood. If these drugs must be used together, frequent monitoring of serum lithium levels is mandatory.
• Potassium-Sparing Diuretics (e.g., Spironolactone, Triamterene, Amiloride): These drugs increase potassium levels. Using them with Quinapril can lead to severe hyperkalemia, which can cause fatal heart arrhythmias.
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., Ibuprofen, Naproxen, Celecoxib): NSAIDs can reduce the antihypertensive effect of Quinapril. Furthermore, in patients who are elderly or have compromised kidney function, the combination can lead to further deterioration of renal function, including acute renal failure.
• Gold (Sodium Aurothiomalate): Nitritoid reactions (symptoms include facial flushing, nausea, vomiting, and hypotension) have been reported rarely in patients on injectable gold therapy and concomitant ACE inhibitor therapy.

• Other Antihypertensives: While often used together, combining Quinapril with other blood pressure meds (like Beta-blockers or Calcium Channel Blockers) increases the risk of hypotension.
• Insulin and Oral Antidiabetics: ACE inhibitors may increase insulin sensitivity. This can occasionally lead to hypoglycemia (low blood sugar), especially in the first few weeks of combined use.
• mTOR Inhibitors (e.g., Temsirolimus, Sirolimus): Patients taking these drugs may be at increased risk for angioedema when starting an ACE inhibitor.

• High-Fat Meals: A high-fat meal can slightly reduce the rate and extent of absorption of Quinapril, though this is usually not clinically significant for most patients.
• Salt Substitutes: Many salt substitutes contain potassium chloride instead of sodium chloride. Using these while taking Quinapril can lead to dangerously high potassium levels.
• Grapefruit: Unlike some calcium channel blockers, Quinapril does not have a major interaction with grapefruit juice.

• Potassium Supplements: These should be avoided unless specifically prescribed by a doctor who is aware you are taking Quinapril.
• St. John's Wort: May potentially reduce the effectiveness of antihypertensive medications, although specific data for Quinapril is limited.
• Natural Licorice: Can cause sodium retention and potassium loss, counteracting the effects of Quinapril.

Quinapril does not typically interfere with most common laboratory tests. However, it may cause a false-positive result in urine tests for acetone using the nitroprusside method. It may also lead to slight increases in blood urea nitrogen (BUN) and serum creatinine.

For each major interaction, the mechanism usually involves either pharmacodynamic synergy (additive effects on blood pressure or potassium) or pharmacokinetic interference (reduced renal clearance). Management typically involves dose adjustment, frequent lab monitoring, or selecting alternative therapies.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous drug interactions.

Quinapril must NEVER be used in the following circumstances:

• History of Angioedema: If a patient has ever experienced angioedema (swelling of the face, lips, tongue, or throat) related to previous treatment with any ACE inhibitor, Quinapril is strictly prohibited. It is also contraindicated in patients with idiopathic or hereditary angioedema. The mechanism involves the accumulation of bradykinin, which can lead to rapid, life-threatening airway obstruction.
• Pregnancy: Due to the high risk of fetal injury and death (teratogenicity), Quinapril is contraindicated in pregnant women. It acts on the fetal RAAS, leading to kidney failure and skull deformities in the developing fetus.
• Concomitant use with Aliskiren in Diabetes: Patients with diabetes mellitus must not take Quinapril and Aliskiren together due to the extreme risk of renal impairment and hyperkalemia.
• Hypersensitivity: Any known allergy to Quinapril hydrochloride or any other ACE inhibitor (e.g., Lisinopril, Enalapril, Ramipril) is a contraindication.

In these situations, the healthcare provider will perform a careful risk-benefit analysis:

• Renal Artery Stenosis: In patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, Quinapril can cause a sharp decline in glomerular filtration rate (GFR), potentially leading to acute renal failure.
• Severe Aortic Stenosis: Patients with fixed left ventricular outflow obstruction may be at risk of decreased coronary perfusion when treated with vasodilators like Quinapril.
• Hyperkalemia: Patients with pre-existing high potassium levels (above 5.0 mEq/L) should be treated with extreme caution.
• Collagen Vascular Disease: Patients with systemic lupus erythematosus (SLE) or scleroderma may be at a higher risk of developing neutropenia or agranulocytosis while taking ACE inhibitors.

Patients who have had a severe allergic reaction to one ACE inhibitor are highly likely to have a similar reaction to Quinapril. There is no known cross-sensitivity between ACE inhibitors and other classes of blood pressure medications like Angiotensin II Receptor Blockers (ARBs), although caution is still advised when switching between these classes in patients with a history of angioedema.

> Important: Your healthcare provider will evaluate your complete medical history, including any past allergic reactions, before prescribing Quinapril.

Quinapril is classified as Pregnancy Category D (using the older FDA system) and carries a significant warning for fetal toxicity. Use of Quinapril during the second and third trimesters is known to cause injury to the developing fetus, including kidney failure, low amniotic fluid (which leads to limb contractures and lung underdevelopment), and skull defects. While data for the first trimester is less definitive, the general clinical consensus is to avoid all ACE inhibitors throughout pregnancy. Women of childbearing age should use effective contraception while taking Quinapril. If pregnancy is confirmed, the drug must be stopped immediately, and a safer alternative, such as methyldopa or labetalol, should be considered under specialist guidance.

Limited data suggest that Quinapril and its active metabolite, quinaprilat, are excreted into human breast milk in very small amounts. While the levels are low, the potential for serious adverse reactions in nursing infants (such as hypotension or kidney issues) cannot be entirely ruled out. Healthcare providers must weigh the benefits of the drug to the mother against the potential risks to the infant. In many cases, alternative antihypertensives with more extensive safety data during lactation (like Enalapril or Captopril) may be preferred.

The safety and effectiveness of Quinapril in children have not been established. Clinical trials for hypertension in the pediatric population have largely focused on other ACE inhibitors like Lisinopril. Therefore, Quinapril is not FDA-approved for use in patients under 18 years of age. Pediatric hypertension is a complex condition that requires management by a specialist who will choose medications with established safety profiles for children.

Clinical studies of Quinapril did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Older adults are also at a higher risk of falls due to orthostatic hypotension (a drop in blood pressure upon standing).

Patients with impaired renal function require lower doses of Quinapril. As the glomerular filtration rate (GFR) decreases, the half-life of quinaprilat increases, leading to higher drug concentrations in the blood. For patients with a CrCl < 30 mL/min, the starting dose is 2.5 mg. These patients must have their serum creatinine and potassium levels monitored frequently, especially during the first few weeks of therapy.

In patients with impaired liver function or cirrhosis, the conversion of the prodrug Quinapril to the active quinaprilat is slower and less efficient. While this doesn't always require a specific dose reduction, it may result in a delayed onset of action. Patients with severe liver disease should be monitored closely for signs of reduced efficacy or unexpected side effects.

> Important: Special populations require individualized medical assessment and frequent monitoring by a qualified healthcare professional.

Quinapril hydrochloride is the hydrochloride salt of quinapril, the ethyl ester prodrug of quinaprilat. Quinaprilat is a non-sulfhydryl, highly potent inhibitor of the angiotensin-converting enzyme (ACE). ACE is a peptidyl dipeptidase that catalyzes the conversion of the relatively inactive decapeptide, angiotensin I, to the potent vasoconstrictor octapeptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. By inhibiting ACE, Quinapril reduces plasma angiotensin II, which leads to decreased vasopressor activity and decreased aldosterone secretion. The latter decrease may result in a small increase in serum potassium. Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity. ACE is identical to kininase II, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of Quinapril remains to be fully elucidated.

Following oral administration, the peak antihypertensive effect of a single dose is usually seen between 2 and 4 hours. The duration of effect is dose-related, and at recommended doses, the antihypertensive effect is maintained for 24 hours in most patients. In patients with heart failure, Quinapril reduces systemic vascular resistance and blood pressure, and increases cardiac output and stroke volume. There is no evidence of rebound hypertension following abrupt withdrawal of the drug, although it is not recommended. Long-term use does not typically lead to the development of pharmacological tolerance.

| Parameter | Value |

|---|---|

| Bioavailability | ~60% (as Quinapril) |

| Protein Binding | ~97% (Quinapril and Quinaprilat) |

| Half-life | ~2 hours (Quinapril); ~25-30 hours (Quinaprilat terminal) |

| Tmax | ~1 hour |

| Metabolism | Hepatic de-esterification to active Quinaprilat |

| Excretion | Renal (61%), Fecal (37%) |

• Molecular Formula: C25H30N2O5·HCl
• Molecular Weight: 474.98 g/mol
• Solubility: Soluble in water and alcohol.
• Structure: Quinapril is a white to off-white amorphous powder. Chemically, it is described as [3S-[2[R(R)], 3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid monohydrochloride.

Quinapril belongs to the ACE inhibitor class of antihypertensives. It is chemically related to other ACE inhibitors such as Lisinopril, Enalapril, and Ramipril. Unlike Lisinopril, which is an active drug, Quinapril is a prodrug that requires activation by the liver.